C2CD5

C2CD5 is a Ca²⁺- and lipid-binding C2-domain protein that controls vesicle fusion, endocytosis, and organelle transport across multiple cell types, linking membrane trafficking to metabolic homeostasis. Its C2 domain mediates Ca²⁺-dependent membrane association; phosphorylation at S197 by Akt2 drives insulin-stimulated GLUT4 vesicle insertion at the plasma membrane in adipocytes, while the same domain is required for MC4R endocytosis in hypothalamic neurons (PMID:21907143, PMID:31666192). C2CD5 forms a stable complex with CDK5 and FIBP that promotes NudEL phosphorylation, enabling dynein force adaptation for intracellular transport of lipid droplets, lysosomes, and mitochondria (PMID:25096995, PMID:30651536). In sympathetic neurons, C2CD5 is essential for catecholamine and norepinephrine secretion; its loss impairs thermogenesis and energy expenditure, producing obesity in knockout mice that is rescued by norepinephrine supplementation (PMID:29378832, PMID:42006349).

1. 2011 High

   Identification of C2CD5 as an Akt2 substrate with Ca²⁺/lipid-binding capacity established it as a regulated membrane-trafficking effector in the insulin-GLUT4 pathway, answering how post-insulin signaling is coupled to vesicle fusion at the plasma membrane.

   Evidence Quantitative phosphoproteomics, S197A mutagenesis, C2-domain lipid/Ca²⁺ binding assays, and live-cell GLUT4 fusion imaging in 3T3-L1 adipocytes

   PMID:21907143

   Open questions at the time

   • Identity of the SNARE or tethering machinery engaged by phospho-C2CD5 at the plasma membrane is unknown
   • Whether C2CD5 acts catalytically or as a scaffold/adaptor during vesicle fusion is unresolved
2. 2014 High

   Discovery that C2CD5 forms a stable trimeric complex with CDK5 and FIBP revealed it as a scaffold required for CDK5 complex integrity, broadening its role beyond adipocyte GLUT4 trafficking to a general cell-biological function.

   Evidence Reciprocal AP-MS (SAINT analysis) and co-IP in non-neuronal cells; RNAi depletion showing interdependent complex stability and effects on proliferation/migration

   PMID:25096995

   Open questions at the time

   • Structural basis for the C2CD5–CDK5–FIBP interaction is unknown
   • Whether C2CD5 modulates CDK5 kinase activity directly or only mediates substrate access is unresolved
3. 2017 Medium

   Linking the C2CD5–CDK5 axis to TGF-β/Smad signaling via GDF15 upregulation showed a route through which this complex modulates radioresistance and invasion in lung cancer cells.

   Evidence RNAi knockdown with GDF15 rescue, Smad pathway reporters, and invasion assays in lung cancer cell lines

   PMID:28880265

   Open questions at the time

   • How C2CD5–CDK5 upregulates GDF15 transcriptionally is not defined
   • Relevance beyond lung cancer cell lines not tested
   • No direct kinase-substrate relationship between CDK5 and GDF15 or Smad components demonstrated
4. 2018 High

   Whole-body KO mice demonstrated that C2CD5 is selectively expressed in catecholaminergic cells (adrenal medulla and sympathetic nerve terminals in fat) and is required for catecholamine secretion, establishing C2CD5 as a neuroendocrine exocytosis regulator governing thermogenesis and energy balance.

   Evidence C2CD5 KO mice with catecholamine ELISA, HSL phosphorylation, metabolic phenotyping, and glucose/insulin tolerance tests

   PMID:29378832

   Open questions at the time

   • Molecular step at which C2CD5 acts in catecholamine vesicle exocytosis is undefined
   • Relative contribution of adrenal medulla versus sympathetic nerve terminals not dissected
5. 2019 High

   Demonstration that the C2CD5–CDK5–14-3-3ε axis phosphorylates NudEL to enhance dynein force adaptation provided a defined molecular mechanism for C2CD5's role in intracellular organelle transport across lipid droplets, lysosomes, and mitochondria.

   Evidence Single-molecule in vivo force measurements on lipid droplets in COS-1 cells, RNAi epistasis, extension to lysosomes and mitochondria

   PMID:30651536

   Open questions at the time

   • Whether C2CD5's C2 domain or its CDK5-scaffolding function is the critical determinant for cargo-specific transport is unresolved
   • Force adaptation measured only in COS-1 cells; relevance in neurons and adipocytes not directly tested
6. 2019 High

   Showing that C2CD5's C2 domain is required for MC4R endocytosis in hypothalamic neurons connected C2CD5's membrane-trafficking function to central appetite regulation, explaining the obesity phenotype of KO mice through impaired receptor internalization.

   Evidence Antibody-feeding endocytosis assay in HA-MC4R-GFP Neuro2A cells, C2-domain deletion mutant, C2CD5 KO mice with PVH MTII injection and metabolic phenotyping

   PMID:31666192

   Open questions at the time

   • Direct binding between C2CD5 and MC4R or its endocytic adaptor not demonstrated
   • Whether C2CD5 facilitates clathrin-dependent or -independent endocytosis of MC4R is unknown
7. 2021 Medium

   Linking C2CD5 loss to defective mitochondrial trafficking and oxidative function in hypothalamic neurons provided a potential explanation for how impaired organelle transport secondary to C2CD5 deficiency might compound MC4R trafficking defects.

   Evidence C2CD5 KO primary hypothalamic neurons and cell lines with electron microscopy, live-cell imaging, and oxygen consumption assays

   PMID:34034255

   Open questions at the time

   • Causal direction between mitochondrial dysfunction and MC4R trafficking defect not established
   • Whether mitochondrial phenotype is dynein/NudEL-dependent is untested
8. 2025 Medium

   Identification of USP5 as a deubiquitinase that stabilizes C2CD5 protein, coupled with evidence that C2CD5 stability activates PI3K/AKT/mTOR/HIF-1α-driven glycolysis, revealed a post-translational control layer for C2CD5 abundance with implications in AML.

   Evidence Co-IP/MS identifying USP5–C2CD5–FIBP–CDK5 complex, ubiquitination assays, USP5 knockdown/overexpression, pathway western blots in AML model

   PMID:41344512

   Open questions at the time

   • Ubiquitin chain type and specific lysine residues on C2CD5 targeted by USP5 not identified
   • Whether PI3K/AKT/mTOR activation is a direct consequence of C2CD5 scaffolding or indirect through CDK5 is unresolved
   • Single study; independent confirmation in non-AML contexts needed
9. 2026 High

   Cell-type-specific conditional KO in DBH+ noradrenergic neurons, with NE rescue of metabolic defects, provided definitive evidence that C2CD5 functions cell-autonomously in sympathetic neurons to control norepinephrine secretion and systemic energy homeostasis.

   Evidence DBH-Cre × C2CD5-flox conditional KO mice with NE secretion measurements, metabolic phenotyping, and NE supplementation rescue

   PMID:42006349

   Open questions at the time

   • Step in the NE vesicle cycle (docking, priming, or fusion) at which C2CD5 acts is not pinpointed
   • Whether the CDK5–NudEL force adaptation mechanism operates in NE secretory vesicle transport is unknown

• The precise molecular mechanism by which C2CD5 promotes vesicle exocytosis — whether through Ca²⁺-dependent membrane docking, CDK5-dependent cytoskeletal force generation, or both — remains to be resolved, as does the structural basis for its multivalent scaffolding of CDK5, FIBP, and 14-3-3ε.
• No high-resolution structure of C2CD5 or its complexes exists
• Relative contribution of C2 domain membrane binding versus CDK5 scaffolding to each trafficking function is unresolved
• Whether C2CD5 possesses any intrinsic catalytic activity is unknown